Peter R Young
Overview
Explore the profile of Peter R Young including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
829
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Jahagirdar R, Zhang H, Azhar S, Tobin J, Attwell S, Yu R, et al.
Atherosclerosis
. 2014 Jul;
236(1):91-100.
PMID: 25016363
Despite the benefit of statins in reducing cardiovascular risk, a sizable proportion of patients still remain at risk. Since HDL reduces CVD risk through a process that involves formation of...
12.
McLure K, Gesner E, Tsujikawa L, Kharenko O, Attwell S, Campeau E, et al.
PLoS One
. 2014 Jan;
8(12):e83190.
PMID: 24391744
Increased synthesis of Apolipoprotein A-I (ApoA-I) and HDL is believed to provide a new approach to treating atherosclerosis through the stimulation of reverse cholesterol transport. RVX-208 increases the production of...
13.
Young P
J Biomol Screen
. 2013 Jul;
18(10):1156-63.
PMID: 23896688
It has now been almost 20 years since the discovery of p38 MAP kinase and its role in inflammatory cytokine synthesis through reverse pharmacology and its subsequent exploration as a...
14.
Green J, Leu K, Worth A, Mortensen R, Martinez D, Schatz P, et al.
Exp Hematol
. 2012 Mar;
40(7):575-87.
PMID: 22406924
Peginesatide is a synthetic, PEGylated, peptide-based erythropoiesis-stimulating agent that is designed and engineered to stimulate specifically the erythropoietin receptor dimer that governs erythropoiesis. Peginesatide has a unique structure that consists...
15.
Singh S, Verma R, Pradeep A, Leu K, Mortensen R, Young P, et al.
PLoS One
. 2012 Jan;
7(1):e29064.
PMID: 22253704
Erythropoietin (EPO) and its cell surface receptor (EPOR) are essential for erythropoiesis; can modulate non-erythroid target tissues; and have been reported to affect the progression of certain cancers. Basic studies...
16.
Feldman S, Krishnamurthy S, Gillanders W, Gittleman M, Beitsch P, Young P, et al.
Cancer
. 2011 Jan;
117(12):2599-607.
PMID: 21226034
Background: The authors prospectively evaluated the performance of a proprietary molecular testing platform using one-step nucleic acid amplification (OSNA) for the detection of metastatic carcinoma in sentinel lymph nodes (SLNs)...
17.
Pan Z, Scheerens H, Li S, Schultz B, Sprengeler P, Burrill L, et al.
ChemMedChem
. 2006 Dec;
2(1):58-61.
PMID: 17154430
No abstract available.
18.
Spencer J, Sendzik M, Oeh J, Sabbatini P, Dalrymple S, Magill C, et al.
Bioorg Med Chem Lett
. 2006 Jul;
16(18):4884-8.
PMID: 16870445
Novel analogs of (-)-saframycin A are described. The analogs are shown to be potent inhibitors of the in vitro growth of several tumor cells in a broad panel and promising...
19.
Buggy J, Cao Z, Bass K, Verner E, Balasubramanian S, Liu L, et al.
Mol Cancer Ther
. 2006 May;
5(5):1309-17.
PMID: 16731764
CRA-024781 is a novel, broad spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) that shows antitumor activity in vitro and in vivo preclinically and is under evaluation in phase I...
20.
Creager A, Geisinger K, Perrier N, Shen P, Shaw J, Young P, et al.
Ann Surg
. 2003 Dec;
239(1):61-6.
PMID: 14685101
Background: The evaluation of sentinel lymph nodes (SLNs) from a woman with lobular cancer of the breast is frequently challenging. Intraoperative imprint cytology (IIC) is equivalent to frozen sectioning for...